Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for hunting that down, stephQB. If there really is a deal as MW has publicly stated just a couple weeks ago
(http://www.investorshub.com/boards/read_msg.asp?message_id=6061729)
then I guess the way to understand it is there is an AGREEMENT, but there is no signed contract/money in the bank, etc....YET. I have to think a signed deal/equity position/money in the bank would certainly be material.
How can another company dictate to BIPH when an announcement is to be made? A signed deal for BIPH technology is a life changing event. Come on MW, let's see what you got!!
Yup, that was it.....thanks again. I'm glad you were online tonight. This IHub computer learning site is great.
Thanks, Dan. You know, I'm one of those still on dial up. A few days ago MSN showed up on my screen with "connection center". I didn't ask for it, it was just there.
I think you're on to something. It does have an accelerator option, normal--faster--fastest. It was set on faster. I reset it to normal, but images still a bit blurry. Maybe when I re-start I will be ok. Thanks for the tip.
Thanks....unchecked it, hit 'apply'....images still a bit blurry. Any other ideas?
Just recently, pictures on websites (like a catalog item or a home photo on a real estate site) I pull up are a bit blurry. I've checked my monitor resolution, etc. and just recently found if I put the cursor on the image, right click and then select 'view original image' that the image blur goes away. I didn't have to do this right-click stuff until just a few days ago.
Would one of you please give me a couple ideas of what's going on? Thank you very much.
Thanks, you guys, for your thoughts on "the deal". I haven't sold any and I'm in under a dollar average. But, I'm still not adding any either because I just don't know what to think about the PR's, hints of a deal, but nothing announced to make it real.
I think any actual deal would have to be announced, and they would just state in SEC filings that terms are confidential. Maybe those types of filings are only for listed stocks? Hmmm, maybe something soon.....
Two weeks ago MW indicated BIPH has reached a deal for "fair value" of BIPH's technology. I have read a few posters who state the money is 'in the bank'. I would think that would be material information and necessary for BIPH to disclose.
What am I missing?
OT!: is this the IDCC Ihub board or some episode of Desperate Housewives? Who cares about your little cat fights and who said what to whom.....HEY, how about that news release from IDCC. Thanks to bulldzr, captainslog, and some others for staying on course. Lurkers annonymous must unite...lol!
Please use "OT" or email/phone one another to carry on your social conversation. Many of us do not have alot of time to go through this board. Thanks very much.
Actually, tech, you and others should just 'be happy'... post here on IHub......BIPH deserves better than RB!!
This is nice from the after the bell PR:
"Mr. Weiner added that Biophan has recently achieved significant progress in the establishment of relationships with manufacturers of several medical devices. "I am pleased to have reached the agreement we were seeking with a preferred partner, achieving fair value for our technology. We look forward to announcing the specifics as soon as we are authorized to do so." "
http://biz.yahoo.com/bw/050415/155390.html?.v=1
I've just returned to read some stock boards...IDCC posters can be found everywhere ...yahoo, RB, AB, IHub...if people are invested in ANY company based on investment chat/message board information they will soon be separated from their bank account, and deservedly so. IMO
Thanks, jimlur, for hanging in there because I'd have thrown in the towel awhile ago on the board monitoring stuff. I, for one, appreciate your doing it.
Has anyone heard from Malko lately? Just curious on his updated 'take' on things......
And remember MW's 'motto' on his Technology Innovations site: "Turning Ideas into Annuities"....gotta like that way of thinking!
http://www.tillc.com/
From today's release: "It is not reasonable to expect every MRI technician to know all this, but it is reasonable to make sure that a pacemaker patient, even one in one thousand, does not die in an MRI coil during a scan," said Mr. Weiner. "The pacemaker industry now has several solutions. It is time for them to take action. It is their ethical imperative."
----------------
renman: do you get any impression from this that some manufacturers in the pacemaker industry are saying "no thanks, Biophan" we plan to go with other solutions...?
It's like we're waiting for the first domino to fall, and then many will others will follow having recognized the strength of the "patent thicket". Come on, MW, there's a whole bunch of longs cheering for you!!
If you've invested in BIPH for the long term, you shouldn't be focused on the last days drops...but the rise from just a couple weeks ago. If you're a trader, you should listen to EP or unknown or renmanaz and others to better your chances of timing the ins and outs. I was hoping for "the deal" to close by the end of March; it didn't; and that's why I will add more when the deal is done and not before. If BIPH shoots up many points and I can't or don't add more, I'm still a happy camper with what I hold. So what's with all the whining on RB? Don't ya know....RB is for sissies?
Oh...got it..good luck to you!
(By the way, same story with cancer and my family...both mother and father with various types....sister. too.)
Hi Bub....re: your comments to Caroln to "put me on the list"...I can't imagine a company's PR/IR department would keep an actual list to notify certain people of any new (spin-off or otherwise) issues in their pipeline. Wouldn't any sort of new issue of anything be more properly made with a formal press release, not individually to people on a list? Maybe I'm missing out on something.
My reason for posting that link to b9 was simply in reference to a comment of his on RB. If BIPH investors would take some more time to poke around all the companies listed in Technology Innovations LLC I think some will be astounded at the scope of interests/patents with which MW is involved or affiliated. I think there's a method to his 'madness'.
Anyway, good luck to us all in this next great week of BIPH investing! I enjoy your kind and courteous posts here and on RB.
to b9molecule on RB:
Regarding your question on Raging Bull "how does BIPH keep finding itself in the sweetspot"....have you checked out this site that MW (via Technology Innovations LLC)is also affiliated with?
http://www.oncovista.com/start_content.html
Hope 'bettinongrace' from RB doesn't mind my reposting this here. I think there's some merit to this thought process:
--------------------------------------------
BSX Investors – The Liberte Stent and BIPH
Disclosure: This is just my (bettinongrace)opinion and my observations
On (2/1) the BSX analyst call a rep. stated that for the foreseeable competition to the Liberte it will be 'increasingly difficult for another company to compete' well if the BIPH tech. Is on the Liberte then that would be a good reason why it might be hard to compete.
The features that the Liberte boasts are a new overall design that makes it more flexible and the delivery will be better. There would be less recoil and it would not turn. (I am not in the med. field so I am sure someone else could elab. better then me on the feature that were discussed)
The more curious to me was the cocky 'we know we are going to take over the market' confidence that they had. The analysts still doubted them by about adding just these two features would make it so much better the Csypher-Velosity from the competition.
But I did not hear much elaboration on the method of delivery. But if you will note that aMRIs holds the US patent for MRI delivery of a stent inserted under an MRI. So BSX would need BIPH to finalize their deal before the drug coated Liberte was released. Which has happened.
Some other thoughts to ponder, why do you think MW would take us to the exchange later this year if the development to market really far off. He did say that the coating was ‘ready to ship’ among other products in January. SBI inked the equity agreement the same day BSX receive FDA approval in Maple Grove, MN on their new R&D site. And finally the Liberte project was started Nov 2003 the same month BSX signed the development deal with BIPH for the joint development agreement. The bare metal Liberte received the CE mark Dec. 2003. So the base Liberte was ready to be tested with the drug coating at this point.
In February the BSX shareholders were a little ticked off because BSX wouldn’t really say why they think the Liberte will be so competitive that it will be increasingly difficult for other competitors to complete and they did not elaborate much on why the delivery procedure is so much better.
Finally, BSX touted loudly how they intend on majorly penetrating the Japan stent market with the new Liberte. Because the Taxus#1 did not open up the Japanese market as they would have hoped as it did in the US. Now our little BIPH popped up again in the same arena BSX has the most interest (Tokyo) international BSX plans to sell the Liberte to during 2005. (I love this stock and MW and BSX) I just cannot wait until the BSX deal is closed "soon" and the plan unfolds.
Just couldn’t resist the pumping opportunity for the newbies.
I say BIPH can use 'nano' references all it wants...
The following directly from Nanoscience Technologies website (www.nanoscience-tech.com) By the way, Steven Katz is NANS Chairman of the Board and is also on the Board of Directors of BIPH)
"The U.S. National Science Foundation has forecasted that the global market for nanotechnology products and services will reach $1 trillion in revenues annually by 2015. By the close of 2006, it is estimated that nanotechnology related industries are expecting gross revenues of $25 billion. Simply put, it will affect almost every aspect of our lives. From medicines to our medical evaluations and diagnosis methods, from the power of our computers to our energy generation, from the food we eat, cars we drive, and airplanes in which we fly to the buildings we live in and the clothes that we wear, early phase products are being deployed today in the marketplace. While the tempo and range of applications of this technology is expanding daily, for every area where we can envision an impact, there will be others no one has thought of to date – new capabilities, new products, and new markets. Given the breadth of impact, in the short- and medium-term this will mainly be a gradual but consistent revolution, creeping into the world around us for decades to come.
Governments worldwide are keenly interested in this science and technology as they glimpse into the future. The United States, the largest known government investor at present, has committed $3.7 billion to research over the next three years through the National Nanotechnology Initiative (NNI) fund. Suffice it to state that the present investment is significant and growing by full integer multiples each year. It is projected that the spending and technological advances realized in this science during in the decades ahead will far exceed our recent several decades in the micro science age.
Because it has been primarily in the research labs, the street person hasn’t been overly aware of its power and promise. It is now being deployed mostly in rudimentary forms, primarily particles and carbon tubes versus 2D or 3D complex structures, in many areas of our industrial complexes including disk drives, stain free fabrics (Nano-Tex fabric sold by Eddie Bauer, Lee Jeans and others), clear sun screens, paints, tire technology, and many others, all applications with measurable leaps in performance.
Life Sciences & Medicine
In life sciences and medicine, it means we are now becoming able to measure and make things on the level at which organisms in the living world, from bacteria to plants to ourselves, do most of their work. Being able to work at this scale empowers us in our control of the biological world and allows us to start borrowing from that world, leveraging the extraordinary inventions that nature has produced through billions of years of evolution.
Materials
In materials, things start to behave differently at the nanoscale. The bulk materials that we have traditionally dealt with are uncontrolled and disordered at small scales. The strongest alloys are still made of crystals the size and shape of which we control only crudely. By comparison, a tiny, hollow tube of carbon atoms, called a carbon nanotube, can be perfectly formed without any imperfections in structure, is remarkably strong, with useful electrical and thermal properties.
When particles get small enough (and qualify as nanoparticles), their mechanical properties change, and the way light and other electromagnetic radiation is affected by them changes (visible light wavelengths are on the order of a few hundred nanometers). Using nanoparticles in composite materials can enhance their strength and/or reduce weight, increase chemical and heat resistance and change the interaction with light and other radiation. While some such composites have been made for decades, the ability to make nanoparticles out of a wider variety of materials is opening up a world of new composites.
...continued."
The brain power associated in and around BIPH is really something. Here's one more tidbit from the Biomed and Technology Innovation sites.
Myotech is an affiliate of Biomed and Technology Innovations.
"MYOTECH, LLC - Jeffrey L.Helfer, CEO - (and BIPH's VP of Engineering)
MYOTECH, LLC intends to commercialize a minimally invasive next-generation Ventricular Assist Device ("VAD"), called the MYOTECH MYO-VAD. The MYO-VAD is a flexible polymer cup that can be installed around the heart in approximately 3 minutes. Incorporating a pneumatically activated liner, the MYO-VAD operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the input and output of blood to life sustaining levels. Following years of research, MYOTECH's Founders have proved in medical studies that their technology works and is ready for commercialization. Prototype devices have been installed in over 700 animals and more than 60 humans. The MYOTECH MYO-VAD avoids stroke, bleeding, and infection complications common to all mechanical blood pumps, the only cardiac assist devices currently available.
The Company has developed a substantial intellectual property portfolio to protect current and future applications of its technologies. MYOTECH is setting up the manufacturing of the MYO-VAD, and is preparing for clinical studies to obtain regulatory approval for using the product to provide the short term support required to treat multiple forms of heart disease. In parallel with these activities, MYOTECH has initiated partnerships to develop the additional diagnostic, therapeutic, and operational capabilities required for the MYO-VAD to participate in follow-on market segments requiring longer term support. CEO, Jeffrey Helfer, has assembled an experienced medical product commercialization team. The Team has proven, industry track records with Johnson and Johnson and Eastman Kodak involving Class II and III medical flagship products that have achieved significant commercial success. The Company is currently seeking to raise $1.5 million of funding from angel investors."
By the way, you gotta love Technology Innovations theme: "Turning ideas into annuities."
It's rather fascinating reading to research the various companies in the holdings/investments of Biomed Solutions and Technology Innovations. One of them is Onco-Vista and it plans "to merge into a publically listed OTC company, and anticipates trading in the US and Germany in early 2005."
Here is the link to their site...amazing stuff...it's a wild ride MW (via his various holdings)is on!
http://www.oncovista.com/start_content.html
Industry news:
Conor Medsystems to evaluate Novartis drugs for stents
Tue Mar 15, 2005 06:55 PM ET
CHICAGO, March 15 (Reuters) - Medical device maker Conor Medsystems Inc.(CONR.O: Quote, Profile, Research) on Tuesday said it signed a deal with Switzerland's Novartis AG (NOVN.VX: Quote, Profile, Research) to test three drug compounds for use with future drug-eluting stents for the treatment of clogged heart arteries.
Under terms of the deal with Novartis, if one compound proves successful, Conor has the option to obtain a worldwide, non-exclusive license to commercialize products combining the compound and its stents.
Stents are tiny wire mesh tubes that prop open heart arteries after fatty deposits are cleared away. In more advanced versions, a drug coating is added to prevent arteries from reclogging.
Menlo Park, California-based Conor is currently in a legal battle with stent leader Boston Scientific Corp.(BSX.N: Quote, Profile, Research) and Angiotech Pharmaceuticals Inc.(ANP.TO: Quote, Profile, Research) over the paclitaxel stent coating Angiotech licenses to Boston Scientific.
Conor is trying to commercialize its own stent using paclitaxel and is attempting to revoke an Angiotech patent relating to the lucrative heart devices, which are expected to generate sales of $5.5 billion in 2005.
Conor's stent design includes built-in reservoirs that help control release of the drug......."
Today BIPH is attending this CRO (Contract Research Organization or Clinical Research Organization)Partnering forum:
"Sachs Associates are pleased to announce the 1st Sachs Bloomberg CRO Partnering Forum run in conjunction with the 4th Annual North America Forum for Investing and Partnering in Biotech and Medtech. The North American Forum is a leading 2 day event which is recognized throughout the industry as the international forum for emerging and established biotech and specialty pharmas.
Over recent years CRO’s have participated in development of some of the most successful drugs in history. However, CRO’s are often still treated by some members of their client base as an expendable commodity. With the importance of CRO’ s increasing this Forum will provide a stage for clinical development professionals to gain practical knowledge in the development of effective clinical partnerships.
This event is specifically designed to present best practices on creating, managing and sustaining clinical outsourcing partnerships that enable more efficient and safe trials.
With sponsors already including Harvard Clinical Research Institute, the CRO Partnering Forum is designed to be one of the most highly transactional forums this year, drawing together leading CRO’s pharmas and biotechs to examine the key issues, including:
~ The value proposition of outsourced clinical research,
~ Global regulatory issues, picking your partner for clinical trials
~ Global outsourcing for international trials
~ Designing your trials
~ Getting your device approved
The CRO Partnering Forum is designed to be one of the most highly transactional forums this year, drawing together leading CRO’s pharmas and biotechs to present best practices on creating, managing and sustaining clinical outsourcing partnerships that enable more efficient and safe trials, as well as highlighting industry developments and providing a marketing platform aimed at the numerous pharma and biotech companies attending the North America Forum."
Mornin', bub...I hope BIPH seeks to upgrade their PR firm as BIPH moves into the big leagues. We need to show some class!
Well, I guess that doesn't matter so much as showing a signed deal or two. When, oh when, will that be?
I'm looking for one in the next two weeks....
Most messages on RB lately are worthless, due to the ignorant nature of recent posters. I've been on other boards before (RB ones, actually) and eventually those wanting decent discussion moved to IHub sites. This is really the better venue to discuss and share research. RB is preschool.
I've been paying attention....bought mine at .045 on 12/29... Yipee!! :)
For those of you with no arthritis or other disabling condition AND who have seen/used the aerobicmouse...would you prefer to use it over the conventional mouse most of us have? Is TRBY targeting a specialized market segment, or featuring/selling the aerobicmouse ergonomics for anyone?
One analyst's summary on the stent wars:
____________________________
Boston Scientific Stent Vulnerable To New Rivals
03.07.05, 12:40 PM ET
Prudential Equity Group downgraded Boston Scientific (nyse: BSX - news - people ) to "underweight" from "neutral," saying recently released trial data indicates a "deteriorating risk/reward profile with little upside." The research firm also lowered its price target to $29 from $35. Data released at the American College of Cardiology (ACC) yesterday showed that the Cypher stent, made by Johnson & Johnson (nyse: JNJ - news - people ), performed better than Boston Scientific's Taxus product. "The data are overwhelmingly positive for Cypher vs. Taxus, traditionally signaling a pending share shift," said Prudential. "Growing signals of safety issues and recurrent data suggesting clinical superiority for the J&J Cypher make near-term share losses more likely, but more importantly in our view, make new entrants more threatening by leaving more unmet needs. We are not predicting dramatic safety issues, but the prospect adds an increasingly binary nature to the stock, with perhaps 50% downside without a stent." The research firm lowered 2005 and 2006 earnings-per-share estimates for Boston Scientific to $1.95 and $1.85, respectively, from $2.25 and $2.35. In addition, a trial for the Endeavor stent, made by Medtronic (nyse: MDT - news - people ), met all of its primary endpoints, raising the potential of competitive risks. Prudential upgraded Medtronic to "overweight" from "neutral weight" and said Taxus safety concerns have given Medtronic a "window at least until Guidant (nyse: GDT - news - people ) arrives to market."
Hi 'hawk...Yes, I agree on the good webcast. I remain optimistic, but sure am anxious to see a deal closed. I'm reluctant to add more shares until something is in concrete....then I'm happy to double-up.
Of course, hindsight will then say I should have bought more right now....but, better safe than sorry.
Good luck to you, too.
Hope this link works, or else you can access tomorrows presentation from BIPH's webpage. It looks like all presenters are webcasting their 'shows'.
http://www.analyst-conference.com/
If you click on the banner area that says 'webcast' you can be alerted to hear MW give the BIPH presentation tomorrow.
Today estimated prophet is esteemed profit!
OT, imalurker....that would be in the Accenture Match Play, I think....
unknown...just wanted to say THANKS for unselfishly sharing all your BIPH DD and posting such on the board info here on IHub. Like most investors, I don't take your research as the total sum of what to read, and I follow your links, research top management, and do my own digging to find out as much as possible.
Are there red flags? Some over on RB seem to think they are not only red... but big, bad and ugly. Hey, it's a development stage company trading OTCBB...yeah, that's a warning, but I think BIPH is a solid opportunity for those who are thorough. I remain cautiously optimistic.
Hah! Just saw others applauding you over on RB...great minds.....?
In the reading I have done, I understand term sheets to be non-binding. Are there any legal types on this board who can elaborate or share what/how the next steps are taken after a term sheet is signed? Is there any idea of a time frame after a term sheet is signed to land something that is binding?
There's lots of talk on RB about BIPH being slow on the draw to get a deal done with BSX and/or others. I've spent the past couple days reading on and off about the BSX and Medinol Ltd "relationship". It gives the reader a much better understanding of how difficult these co-working agreements and all the pitfalls.
MW is on the line to finalize with aMRIS by the end of the month. We'll see. I think it will happen. If he gets it done it will add to the credibility of BIPH, and then let's see if that gets us closer to actually signing the term sheet with BSX.
The PARS flop... article in Haaretz:
http://www.haaretz.com/hasen/spages/536276.html
OT, OT: "TerryH..."It's like you come onto this planet with a crayon box. Now you may get the 8-pack, you may get the 16-pack, but it's all in what you do with the crayons, the colors that you're given. And don't worry about drawing within the lines, or coloring outside the lines. I say, color outside the lines. You know what I mean? Color right off the page. Don't box me in! We're in motion to the ocean. We are not landlocked, I'll tell you that. So where do you want out?"
related OT:
Europe upholds Angiotech's stent patent
http://biz.yahoo.com/prnews/050124/to029_1.html
European Patent office maintains validity of Angiotech's paclitaxel-eluting stent patent
Monday January 24, 11:46 am ET
VANCOUVER, Jan. 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced a favorable decision on its European Patent (No. 0706 376) from the European Patent Office Opposition Division.
The European Patent Office maintained the validity of Angiotech's patent with various claims, including claims to stents coated with paclitaxel and a polymeric carrier. This decision reaffirms Angiotech's continued patent protection in Europe.
This patent is one of many in Angiotech's portfolio of patents protecting its pioneering technology, including the Boston Scientific TAXUS(TM) stent program.
Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, is dedicated to enhancing the performance of medical devices and biomaterials through the innovative uses of pharmacotherapeutics. To find out more about Angiotech Pharmaceuticals, Inc., please visit our website at www.angiotech.com. <<